Phase 3 N=212 Multi-Center Study of New Medications to Treat Vaginal Infections
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 25 Participants — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Neuroendocrine Tumors · Pancreatic Neoplasms
Primary: Objective Response Rate — 3; 14 Participants
Phase 2 N=144 Olanzapine for Nausea After Surgery
Postoperative Nausea and Vomiting
Primary: Number of Participants With Nausea and/or Vomiting — 10; 26 Participants — p=0.003
Phase 4 N=100 Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery
Breast Surgery
Primary: Numeric Rating Scale Pain Scores — 3.0; 0 score on a scale — p=0.0011
N/A N=194 Post-endodontic Pain Survey
Postoperative Pain · Endodontic Disease · Obturation
Primary: Visual Analogue Scale (VAS) — 4.06; 2.68; 2.41; 2.27 score on a scale
N/A N=348 Software Treatment for Actively Reducing Severity of ADHD
Attention Deficit Disorder With Hyperactivity
Primary: Test of Variables of Attention-Attention Performance Index (Change From Baseline to Posttreatment) — 0.93; 0.03 z-score
Phase 1 N=7 Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Recommended Phase 2 Dose of BI 836826 in Combination With Ibrutinib
Phase 2 N=19 Abdominal Nerve Blockade in Chronic Heart Failure.
Heart Failure
Primary: Exercise Capacity as Measured by Peak Oxygen Uptake (Peak VO2) — 9.1; 9.8 mL/kg/min — p=0.053
Phase 2 N=19 Effect of Evolocumab on Coronary Endothelial Function
Human Immunodeficiency Virus · Coronary Artery Disease
Primary: Coronary Endothelial Function as Assessed by Percent Coronary Artery Area Change With Isometric Handgrip Exercise — 5.6 percent change in coronary artery area
Phase 2 N=23 Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Lung Cathelicidin Level at 8 Weeks — -65.5 pg/mL — p=0.21
Phase 4 N=51 A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
Depression
Primary: Change From Baseline on Symptoms of Depression Questionnaire (SDQ) — 3.7; 3.7; 3.5; 3.5 score on a scale — p=0.46
Phase 2 N=1,044 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.99; 11.60; 7.13; 7.36 months — p== 0.872
Phase 2 N=39 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Malignant Glioma
Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants
Phase 1 N=2 Dose Escalation PfSPZ-CVac
Malaria
Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants
Phase 2 N=127 Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis (NASH)
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 70.6; 71.4; 61.5 percentage of participants